Cognitive dysfunction in psychiatric disorders: characteristics, causes and the quest for improved therapy
Open accessThe DOI matches its Crossref record; 273 of the 274 references it cites were found in a registry or an index.
Abstract
Studies of psychiatric disorders have traditionally focused on emotional symptoms such as depression, anxiety and hallucinations. However, poorly controlled cognitive deficits are equally prominent and severely compromise quality of life, including social and professional integration. Consequently, intensive efforts are being made to characterize the cellular and cerebral circuits underpinning cognitive function, define the nature and causes of cognitive impairment in psychiatric disorders and identify more effective treatments. Successful development will depend on rigorous validation in animal models as well as in patients, including measures of real-world cognitive functioning. This article critically discusses these issues, highlighting the challenges and opportunities for improving cognition in individuals suffering from psychiatric disorders.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Because memory impairments were observed in MDD patients (Dere et al. 2010; Millan et al. 2012), the recovery of memory deficits in animal models of AD after administration of DHF could be expected.”
From Neurotrophic factors and neuroplasticity pathways in the pathophysiology and treatment of depression (2018) · cites this paper as Millan et al. 2012
In the citing paper
“Executive dysfunction (ED) is a transdiagnostic factor in various psychopathologies (13,14)”
From Impact of Childhood Trauma on Executive Function in Adolescence—Mediating Functional Brain Networks and Prediction of High-Risk Drinking (2020) · cites this paper as [13]
In the citing paper
“Pair-bond formation is a social cognitive process that involves both social recognition and social reward (27–29) and models a human attachment relationship far more closely than do the social interactions of adult mice or rats.”
From Chronic intranasal oxytocin causes long-term impairments in partner preference formation in male prairie voles (2013) · cites this paper as [27]
In the citing paper
“The prairie vole (Microtus ochrogaster), a socially monogamous rodent native to the American Midwest (24), is the premier animal model for the neurobiology of social bonding (25) and increasingly used to screen drugs that have therapeutic potential for social disorders such as autism (26,27).”
From Chronic intranasal oxytocin causes long-term impairments in partner preference formation in male prairie voles (2013) · cites this paper as [27]
In the citing paper
“The pathways whereby this effect occurs are opaque; changes in appetite and energy balance may have negative effects on cognition because interference in the metabolism of glucose may lead to insulin resistance [84], abnormal neurotransmitter turnover, mitochondrial dysfunction, and energy deficits, as well as changes in neural plasticity [85].”
From Cognitive remission: a novel objective for the treatment of major depression? (2016) · cites this paper as [85]
3 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Items 201–273 of 273
Stefani, M. R., & Moghaddam, B. (2010) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2010.01.028 · Cited by 100
MicroRNAs in Mental Health: From Biological Underpinnings to Potential Therapies
Hunsberger, J. G., Austin, D. R., Chen, G., & Manji, H. K. (2009) · NeuroMolecular Medicine · doi:10.1007/s12017-009-8070-5 · Cited by 98
Bustillo, J. R., Chen, H., Gasparovic, C., Mullins, P., Caprihan, A., Qualls, C., Apfeldorf, W., Lauriello, J., & Posse, S. (2011) · Biological Psychiatry · doi:10.1016/j.biopsych.2010.08.024 · Cited by 96
Vaidya, C. J., & Stollstorff, M. (2008) · Developmental Disabilities Research Reviews · doi:10.1002/ddrr.40 · Cited by 95
Dewachter, I., Ris, L., Jaworski, T., Seymour, C. M., Kremer, A., Borghgraef, P., De Vijver, H., Godaux, E., & Van Leuven, F. (2009) · Neurobiology of Disease · doi:10.1016/j.nbd.2009.04.003 · Cited by 94
Apud, J. A., & Weinberger, D. R. (2007) · CNS Drugs · doi:10.2165/00023210-200721070-00002 · Cited by 90
Mu, Q., Johnson, K. A., Morgan, P. S., Grenesko, E. L., Molnar, C., Anderson, B. S., Nahas, Z. H., Kozel, F. A., Köse, S., Knable, M. B., et al. (2007) · Schizophrenia Research · doi:10.1016/j.schres.2007.03.033 · Cited by 90
Genetic inactivation of D-amino acid oxidase enhances extinction and reversal learning in mice
Labrie, V., Duffy, S., Wang, W., Barger, S. W., Baker, G. B., & Roder, J. C. (2009) · Learning & Memory · doi:10.1101/lm.1112209 · Cited by 89
Perisomatic inhibition and cortical circuit dysfunction in schizophrenia
Lewis, D. A., Fish, K. N., Arion, D., & Gonzalez-Burgos, G. (2011) · Current Opinion in Neurobiology · doi:10.1016/j.conb.2011.05.013 · Cited by 87
d-Serine and a glycine transporter-1 inhibitor enhance social memory in rats
Shimazaki, T., Kaku, A., & Chaki, S. (2010) · Psychopharmacology · doi:10.1007/s00213-010-1794-y · Cited by 87
The Therapeutic Potential of D-Amino Acid Oxidase (DAAO) Inhibitors
Smith, S. M., Uslaner, J. M., & Hutson, P. H. (2010) · The Open Medicinal Chemistry Journal · doi:10.2174/1874104501004020003 · Cited by 84
Neurobehavioral Abnormalities in First-Degree Relatives of Individuals With Autism
Mosconi, M. W., Kay, M., D’Cruz, A.-M., Guter, S., Kapur, K., Macmillan, C., Stanford, L. D., & Sweeney, J. A. (2010) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2010.87 · Cited by 84
Self-citationWei, C. J., Singer, P., Coelho, J., Boison, D., Feldon, J., Yee, B. K., & Chen, J.-F. (2011) · Learning & Memory · doi:10.1101/lm.2136011 · Cited by 83
Watson, D. J. G., Marsden, C. A., Millan, M. J., & Fone, K. C. F. (2012) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145711000435 · Cited by 82
Self-citationStructural and functional brain imaging in adult attention-deficit/hyperactivity disorder
Cubillo, A., & Rubia, K. (2010) · Expert Review of Neurotherapeutics · doi:10.1586/ern.10.4 · Cited by 80
Neuropsychologic effects of neuromodulation techniques for treatment-resistant depression: A review
Moreines, J. L., McClintock, S. M., & Holtzheimer, P. E. (2011) · Brain Stimulation · doi:10.1016/j.brs.2010.01.005 · Cited by 78
Roussos, P., Giakoumaki, S. G., & Bitsios, P. (2009) · Biological Psychiatry · doi:10.1016/j.biopsych.2009.07.008 · Cited by 77
Loiseau, F., & Millan, M. J. (2008) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2008.07.012 · Cited by 76
Self-citationAre we studying and treating schizophrenia correctly?
Swerdlow, N. R. (2011) · Schizophrenia Research · doi:10.1016/j.schres.2011.05.004 · Cited by 76
Histamine H3 Antagonists for Treatment of Cognitive Deficits in CNS Diseases
Raddatz, R., Tao, M., & Hudkins, R. L. (2010) · Current Topics in Medicinal Chemistry · doi:10.2174/156802610790411027 · Cited by 76
Cuijpers, P., Van Straten, A., Hollon, S. D., & Andersson, G. (2010) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.2009.01513.x · Cited by 74
Pharmacology of protein kinase C activators: Cognition-enhancing and antidementic therapeutics
Sun, M., & Alkon, D. L. (2010) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2010.03.001 · Cited by 74
Coles, M. E., Turk, C. L., & Heimberg, R. G. (2007) · Cognitive Behaviour Therapy · doi:10.1080/16506070601070459 · Cited by 72
Treatment with valproic acid ameliorates ADHD symptoms in fragile X syndrome boys
Torrioli, M., Vernacotola, S., Setini, C., Bevilacqua, F., Martinelli, D., Snape, M., Hutchison, J. A., Di Raimo, F. R., Tabolacci, E., & Neri, G. (2010) · American Journal of Medical Genetics Part A · doi:10.1002/ajmg.a.33484 · Cited by 71 · cited 1×
“Furthermore, valproate also improved social cognition and attentio”
BackgroundErtuğrul, A., Salancı, B. V., Başar, K., Oğuz, K. K., Demir, B., Ergün, E. L., Şentürk, S., Erbaş, B., Cila, A., & Uluğ, B. (2009) · Psychiatry Research Neuroimaging · doi:10.1016/j.pscychresns.2009.04.007 · Cited by 68
Language, cognition and the cerebellum: Grappling with an enigma
Beaton, A., & Mariën, P. (2010) · Cortex · doi:10.1016/j.cortex.2010.02.005 · Cited by 66
Doron, K. W., Funk, C. M., & Glickstein, M. (2009) · Brain Research · doi:10.1016/j.brainres.2009.10.029 · Cited by 66
Metabotropic glutamate receptor subtype 5 antagonism in learning and memory
Simonyi, A., Schachtman, T. R., & Christoffersen, G. R. J. (2010) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2009.12.039 · Cited by 66
Keedy, S. K., Rosen, C., Khine, T., Rajarethinam, R., Janicak, P. G., & Sweeney, J. A. (2009) · Psychiatry Research: Neuroimaging · doi:10.1016/j.pscychresns.2008.06.003 · Cited by 64
Self-citationPhosphodiesterase Inhibitors as Potential Cognition Enhancing Agents
Schmidt, C. (2010) · Current Topics in Medicinal Chemistry · doi:10.2174/156802610790411009 · Cited by 64
Mailliet, F., Qi, H., Rocher, C., Spedding, M., Svenningsson, P., & Jay, T. M. (2008) · Experimental Neurology · doi:10.1016/j.expneurol.2008.02.030 · Cited by 63
Self-citationManahan‐Vaughan, D., Wildförster, V., & Thomsen, C. (2008) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2008.06433.x · Cited by 63
Modafinil modulation of the default mode network
Minzenberg, M. J., Yoon, J. H., & Carter, C. S. (2011) · Psychopharmacology · doi:10.1007/s00213-010-2111-5 · Cited by 63
Self-citationHeinrichs, R. W., Ammari, N., Miles, A. A., & Vaz, S. M. (2008) · Schizophrenia Bulletin · doi:10.1093/schbul/sbn095 · Cited by 63
Hashimoto, R., Ohi, K., Yasuda, Y., Fukumoto, M., Iwase, M., Iike, N., Azechi, M., Ikezawa, K., Takaya, M., Takahashi, H., et al. (2010) · American Journal of Medical Genetics Part B: Neuropsychiatric Genetics · doi:10.1002/ajmg.b.31123 · Cited by 61
Theory of mind in obsessive-compulsive disorder: Comparison with healthy controls
Sayın, A., Oral, N., Utku, Ç., Baysak, E., & Candansayar, S. (2010) · European Psychiatry · doi:10.1016/j.eurpsy.2009.09.002 · Cited by 59
Saavedra-Velez, C., Yusim, A., Anbarasan, D., & Lindenmayer, J.-P. (2009) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.07r03982 · Cited by 59
Dorey, R., Piérard, C., Shinkaruk, S., Tronche, C., Chauveau, F., Baudonnat, M., & Béracochéa, D. (2011) · Neuropsychopharmacology · doi:10.1038/npp.2011.152 · Cited by 58
de Bruin, N. M. W. J., Prickaerts, J., Lange, J. H. M., Akkerman, S., Andriambeloson, E., de Haan, M., Wijnen, J., Drimmelen, M. V., Hissink, E., Heijink, L., et al. (2010) · Neurobiology of Learning and Memory · doi:10.1016/j.nlm.2010.01.010 · Cited by 58
Attention-modulating effects of cognitive enhancers
Levin, E. D., Bushnell, P. J., & Rezvani, A. H. (2011) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2011.02.008 · Cited by 57
Matheson, S. L., Green, M. J., Loo, C. K. A., & Carr, V. J. (2010) · Schizophrenia Research · doi:10.1016/j.schres.2010.01.002 · Cited by 57
Egashira, N., Mishima, K., Iwasaki, K., Oishi, R., & Fujiwara, M. (2009) · Journal of Pharmacological Sciences · doi:10.1254/jphs.08r14fm · Cited by 56
Higuchi, Y., Sumiyoshi, T., Kawasaki, Y., Matsui, M., Arai, H., & Kurachi, M. (2008) · Schizophrenia Research · doi:10.1016/j.schres.2008.01.020 · Cited by 54
Systems genetics for drug target discovery
Penrod, N. M., Sallari, R. C., & Moore, J. H. (2011) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2011.07.002 · Cited by 51
Szulc, A., Galinska, B., Tarasow, E., Waszkiewicz, N., Konarzewska, B., Poplawska, R., Bibulowicz, D., Simonienko, K., & Walecki, J. (2011) · Pharmacopsychiatry · doi:10.1055/s-0031-1279739 · Cited by 51
Muscarinic Agonists for the Treatment of Cognition in Schizophrenia
Sellin, A. K., Shad, M. U., & Tamminga, C. A. (2008) · CNS Spectrums · doi:10.1017/s1092852900014048 · Cited by 50
Functional Magnetic Resonance Imaging of Effects of a Nicotinic Agonist in Schizophrenia
Tregellas, J. R., Olincy, A., Johnson, L., Tanabe, J., Shatti, S., Martin, L. F., Singel, D., Du, Y. P., Soti, F., Kem, W. R., et al. (2010) · Neuropsychopharmacology · doi:10.1038/npp.2009.196 · Cited by 50
Neurocognitive profile analysis in obsessive-compulsive disorder
BURDICK, K. E., ROBINSON, D. G., MALHOTRA, A. K., & SZESZKO, P. R. (2008) · Journal of the International Neuropsychological Society · doi:10.1017/s1355617708080727 · Cited by 50 · cited 1×
“There are conditions in which a failure to forget or 'inhibit' is a characteristic symptom: for example, intrusive thoughts in obsessive compulsive disorder (OCD”
BackgroundModi, M. E., & Young, L. J. (2011) · Biological Psychiatry · doi:10.1016/j.biopsych.2011.01.026 · Cited by 47 · cited 1×
“Furthermore, D -cycloserine and oxytocin might be especially effective for treating social cognitive deficits in ASD when coupled with behavioural therapies that likewise reinforce social learnin”
BackgroundSelf-citationMillan, M. J., & Brocco, M. (2008) · Therapies · doi:10.2515/therapie:2008041 · Cited by 47
Self-citationLevallet, G., Hotte, M., Boulouard, M., & Dauphin, F. (2008) · Psychopharmacology · doi:10.1007/s00213-008-1283-8 · Cited by 47
AMPA receptor potentiators as cognitive enhancers.
O'Neill, M. J., & Dix, S. L. (2007) · PubMed · Cited by 45
Roberts, B. M., Holden, D., Shaffer, C. L., Seymour, P. A., Menniti, F. S., Schmidt, C. J., Williams, G. V., & Castner, S. A. (2010) · Behavioural Brain Research · doi:10.1016/j.bbr.2010.03.039 · Cited by 45
Cognitive effects of muscarinic M1 functional agonists in non-human primates and clinical trials.
McArthur, R. A., Gray, J. A., & Schreiber, R. (2010) · PubMed · Cited by 44
Pharmacological Strategies for Enhancing Cognition in Schizophrenia
Barch, D. M. (2010) · Current topics in behavioral neurosciences · doi:10.1007/7854_2010_39 · Cited by 42
Vanderhasselt, M.-A., de Raedt, R., Baeken, C., Leyman, L., & D'haenen, H. (2009) · The World Journal of Biological Psychiatry · doi:10.1080/15622970701816514 · Cited by 40
Vinkers, C. H., Mirza, N. R., Olivier, B., & Kahn, R. S. (2010) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2010.513382 · Cited by 39
Kas, M. J., Krishnan, V., Gould, T. D., Collier, D. A., Olivier, B., Lesch, K., Domenici, E., Fuchs, E., Gross, C. T., & Ċastrén, E. (2011) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2010.12.001 · Cited by 38
Reversal of Ketamine-Induced Working Memory Impairments by the GABAAα2/3 Agonist TPA023
Castner, S. A., Arriza, J. L., Roberts, J. C., Mrzljak, L., Christian, E. P., & Williams, G. V. (2010) · Biological Psychiatry · doi:10.1016/j.biopsych.2010.01.001 · Cited by 37
RGS14 at the interface of hippocampal signaling and synaptic plasticity
Vellano, C. P., Lee, S. E., Dudek, S. M., & Hepler, J. R. (2011) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2011.07.005 · Cited by 37
Applied Strategies Towards EEG/MEG Biomarker Identification in Clinical and Cognitive Research
Sakkalis, V. (2011) · Biomarkers in Medicine · doi:10.2217/bmm.10.121 · Cited by 37
The Role of Alpha2-Adrenergic Agonists in Attention-Deficit/Hyperactivity Disorder
Sallee, F. R. (2010) · Postgraduate Medicine · doi:10.3810/pgm.2010.09.2204 · Cited by 37
Liem-Moolenaar, M., Zoethout, R., de Boer, P., Schmidt, M., de Kam, M., Cohen, A., Franson, K. L., & van Gerven, J. (2010) · Journal of Psychopharmacology · doi:10.1177/0269881109106942 · Cited by 33
Cognitive functions and the state of nonspecific brain systems in panic disorders
Гордеев, С. А. (2008) · Neuroscience and Behavioral Physiology · doi:10.1007/s11055-008-9036-z · Cited by 32
The fear circuitry in panic disorder and its modulation by cognitive-behaviour therapy interventions
de Carvalho, M. R., Rozenthal, M., & Nardi, A. (2009) · World Journal of Biological Psychiatry · doi:10.1080/15622970903178176 · Cited by 31
Saletu, M., Anderer, P., Saletu-Zyhlarz, G. M., Mandl, M., Saletu, B., & Zeitlhofer, J. (2009) · Sleep Medicine · doi:10.1016/j.sleep.2008.12.005 · Cited by 29
Self-citationVyas, N. S., Patel, N., Nijran, K. S., AL-NAHHAS, A. M., & Puri, B. K. (2010) · Expert Review of Neurotherapeutics · doi:10.1586/ern.10.160 · Cited by 29
Oculomotor and Neuropsychological Effects of Antipsychotic Treatment for Schizophrenia
Hill, S. K., Reilly, J. L., Harris, M. S. H., Khine, T., & Sweeney, J. A. (2007) · Schizophrenia Bulletin · doi:10.1093/schbul/sbm112 · Cited by 28
Self-citationGozes, I. (2010) · Peptides · doi:10.1016/j.peptides.2010.10.030 · Cited by 27
MicroRNAs in Memory Processing
Fischbach, S., & Carew, T. J. (2009) · Neuron · doi:10.1016/j.neuron.2009.09.007 · Cited by 27
Using MRI to measure drug action: caveats and new directions
Murphy, S. E., & Mackay, C. E. (2010) · Journal of Psychopharmacology · doi:10.1177/0269881110372547 · Cited by 23
Millan, M. J. (2008) · Elsevier eBooks · doi:10.1016/b978-0-12-373861-5.00001-1 · Cited by 23
Self-citationDIE ARCHITEKTUR DER MENSCHLICHEN SEHBAHN.
Rönne, H. (1944) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1944.tb09288.x · Cited by 4
Cited by
Kahn, R. S., Sommer, I. E., Murray, R. M., Meyer-Lindenberg, A., Weinberger, D. R., Cannon, T. D., O'Donovan, M., Correll, C. U., Kane, J. M., van Os, J., et al. (2015) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2015.67 · Cited by 1,124
Self-citationMcIntyre, R. S., Alsuwaidan, M., Baune, B. T., Berk, M., Demyttenaere, K., Goldberg, J. F., Gorwood, P., Ho, R., Kasper, S., Kennedy, S. H., et al. (2023) · World Psychiatry · doi:10.1002/wps.21120 · Cited by 836
Self-citationFox, K. C. R., Nijeboer, S., Dixon, M. L., Floman, J. L., Ellamil, M., Rumak, S. P., Sedlmeier, P., & Christoff, K. (2014) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2014.03.016 · Cited by 804
Brunoni, A. R., & Vanderhasselt, M.-A. (2014) · Brain and Cognition · doi:10.1016/j.bandc.2014.01.008 · Cited by 669
Phillips, K. A., Bales, K. L., Capitanio, J. P., Conley, A., Czoty, P. W., ‘t Hart, B. A., Hopkins, W. D., Hu, S., Miller, L. A., Nader, M. A., et al. (2014) · American Journal of Primatology · doi:10.1002/ajp.22281 · Cited by 612
Metadata
- Authors
- Millan, M. J., Agid, Y., Brüne, M., Bullmore, E. T., Carter, C. S., Clayton, N. S., Connor, R., Davis, S., Deakin, B., DeRubeis, R. J., Dubois, B., Geyer, M. A., Goodwin, G. M., Gorwood, P., Jay, T. M., Joëls, M., Mansuy, I. M., Meyer-Lindenberg, A., Murphy, D., Rolls, E., Saletu, B., Spedding, M., Sweeney, J., Whittington, M., & Young, L. J.
- Affiliations
- Institut de Recherches Internationales Servier (France) (FR)
- Pitié-Salpêtrière Hospital (FR)
- University Hospitals of the Ruhr-University of Bochum (DE)
- University of Cambridge (GB)
- University of California, Davis (US)
- University of Massachusetts Dartmouth (US)
- Université Paris-Sud (FR)
- University of Pennsylvania (US)
- Institut du Cerveau (FR)
- University of California San Diego (US)
- Warneford Hospital (GB)
- Inserm (FR)
- University Medical Center Utrecht (NL)
- University of Zurich (CH)
- King's College London (GB)
- University of Warwick (GB)
- Medical University of Vienna (AT)
- Servier (France) (FR)
- The University of Texas Southwestern Medical Center (US)
- Newcastle University (GB)
- Emory University (US)
- Corresponding author
- Millan, Mark J.
- ORCID
- Millan, Mark J.
- Brüne, Martin
- Bullmore, Edward T.
- Carter, Cameron S.
- Clayton, Nicola S.
- Connor, Richard
- Davis, Sabrina
- DeRubeis, Robert J.
- Dubois, Bruno
- Geyer, Mark A.
- Goodwin, Guy M.
- Gorwood, Philip
- Jay, Thérèse M.
- Joëls, Marian
- Mansuy, Isabelle M.
- Murphy, Declan
- Rolls, Edmund
- Spedding, Michael
- Sweeney, John
- Whittington, Miles
- Young, Larry J.
- Venue
- Nature Reviews Drug Discovery
- Published
- 2012-02
- Volume
- 11
- Issue
- 2
- Pages
- 141-168
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W2080092700
- Cited by
- 1,292
- References
- 274
- Citations by year
- 2026: 80 · 2025: 110 · 2024: 107 · 2023: 104 · 2022: 105 · 2021: 97 · 2020: 96 · 2019: 97 · 2018: 86 · 2017: 74 · 2016: 87 · 2015: 75 · 2014: 63 · 2013: 78 · 2012: 30
- FWCI
- 10.62
- Type
- journal article
- Language
- en
- Open access
- green
- doi.org
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Reviews Drug Discovery (publishedVersion)
- PubMed (publishedVersion)
- HAL (submittedVersion)
- Research Portal (King's College London) (submittedVersion)
- Research Explorer (The University of Manchester) (submittedVersion)
- Zurich Open Repository and Archive (University of Zurich) (submittedVersion)
- Newcastle University ePrints (Newcastle Univesity)
- Funders
- National Institute for Health and Care Research (RP-PG-0606-1045, NF-SI-0509-10229)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Keywords
- cognitive impairment, mental illness, depression, anxiety, hallucinations, translational research, animal models, cognitive function, quality of life, social and professional integration, cognitive therapy
- MeSH terms
- Mental Disorders, Brain, Cognition, Cognition Disorders, Humans, Magnetic Resonance Imaging, Neuropsychological Tests, Psychomotor Performance, Risk Factors, Stress, Psychological, Nootropic Agents, Genetic Predisposition to Disease, Epigenesis, Genetic
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.